Chi-Med cuts su­r­u­fa­tinib PhI­II short; FDA green­lights Her­ceptin copy­cat from Am­gen, Al­ler­gan

→ One of Chi-Med’s late-stage fa­vorites is grad­u­at­ing ear­ly from its Phase III study, hav­ing met its pri­ma­ry end­points at in­ter­im analy­sis. The Hong Kong-head­quar­tered biotech left out the num­bers in its brief state­ment, which not­ed that su­r­u­fa­tinib hit a PFS goal among pa­tients with ex­tra-pan­cre­at­ic neu­roen­docrine tu­mors. CEO Chris­t­ian Hogg has tapped the drug, along­side savoli­tinib, for ap­provals over the next two years to fol­low up on the land­mark OK for fruquin­tinib in Chi­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER